These drugs help to inhibit tumor growth, block new blood vessel formation, and stimulate the body's immune system to fight cancer. The rising incidence of renal cell carcinoma across the globe due to lifestyle changes, growing geriatric population, and rising pollution levels is fueling the demand for kidney cancer drugs.

Global kidney cancer drugs market is estimated to be valued at US$ 7.15 Bn in 2024 and is expected to exhibit a CAGR of 9.7% over the forecast period 2024 to 2031.
​
Kidney Cancer Drugs Market Demand is moving towards targeted therapy and immunotherapy which is spurring the growth of the market. These drugs are effective, have fewer side effects and improved survival rates compared to chemotherapy. Due to the advantages offered by kidney cancer drugs, their uptake is growing among patients suffering from renal cell carcinoma leading to the high growth of the market.

Key Takeaways

Key players operating in the kidney cancer drugs are Celanese Corporation, British Petroleum, Eastman Chemical Company, Jiangsu Sopo (Group) Co., Ltd., China Petroleum & Chemical Corporation (Sinopec), Lyondell Basell Industries, Saudi Basic Industries Corporation (SABIC), Mitsubishi Chemical Company, PetroChina Co. Ltd., PetroChina Co. Ltd., BASF SE. These players are actively involved in new product launches, joint ventures, and strategic collaborations to expand their kidney cancer drugs portfolio and global presence.

The key opportunities in the kidney cancer drugs market include business expansion in emerging countries, targeting new patient segments, and development of advanced combination therapies. Major players are focusing on establishing their manufacturing and distribution footprint in Asia Pacific and Latin America owing to high market potential.

Global expansion is a key growth strategy adopted by the leading players. Celgene Corporation acquired IFM Therapeutics to strengthen its research capabilities. Sinopec entered into partnerships with European firms to co-develop and market cancer drugs in China. Strategic collaborations and mergers & acquisitions enabled companies to penetrate new markets across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Market Drivers:

Rising incidence of renal cell carcinoma is a major factor driving the kidney cancer drugs market. According to WHO, over 400,000 new cases of kidney cancer are recorded annually worldwide. Growing geriatric population and lifestyle changes such as smoking, obesity, and high blood pressure are leading to a surge in RCC patients. This is augmenting the demand for effective kidney cancer drugs for treatment.

Targeted therapies and immunotherapies show great promise in treating advanced kidney cancer. Drugs such as tyrosine kinase inhibitors and mTOR inhibitors have significantly improved the survival of kidney cancer patients. Their superior efficacy and safety over chemotherapy is boosting their adoption rate among patients and healthcare professionals, thereby fueling market growth.

Market Restrains:

High cost of targeted therapies used for kidney cancer treatment acts as a major barrier. Drugs such as cabozantinib and axitinib have an annual cost of over US$ 100,000 which impacts affordability. This results in underutilization of life-saving drugs in low and middle-income countries.

Emergence of drug resistance is another challenge faced by the market. Continuous and prolonged use of therapies leads to resistance development in cancer cells limiting their effectiveness over time. This necessitates the development of new drug regimens which incurs huge costs for pharmaceutical companies.

Segment Analysis
The kidney cancer drugs market is dominated by the targeted therapy sub-segment. Targeted therapy drugs directly block the growth and spread of cancer by interfering with specific molecules needed for tumor growth and progression. This sub-segment accounts for over 50% of the total kidney cancer drugs market share owing to increasing R&D activities and rising demand for precision medicines over traditional chemotherapy for treatment of kidney cancer.

Global Analysis
North America is the fastest growing and largest regional market for kidney cancer drugs currently, and is expected to continue to dominate over the forecast period. High prevalence of kidney cancer along with innovative targeted therapies approved in the region drives market growth. Asia Pacific is poised to be the fastest growing regional market through 2031, with China and India being growth hotspots. Rising healthcare expenditures, large patient population and increasing awareness are key factors fueling kidney cancer drugs demand in Asia Pacific.
Get more insights on This Topic- Kidney Cancer Drugs Market